logo
Experts Say This Common Bedtime Habit "Can Create A Perfect Environment For Fungus And Bacteria"

Experts Say This Common Bedtime Habit "Can Create A Perfect Environment For Fungus And Bacteria"

Buzz Feed07-03-2025
Old wives' tales warn that sleeping with wet hair can make you sick or increase your chances of catching a cold, but there isn't any scientific evidence that it can directly cause respiratory illnesses. However, there are risks associated with sleeping with wet hair, including hair and scalp damage. And fungus is involved.
When you wake up in the morning after sleeping on wet hair, you may find your hair smelling like mildew, harboring a stale and damp aroma similar to the smell of the early stages of mold forming, said Dusty Schlabach, a hairstylist and owner of Thairapy Salon in South Pasadena, California.
'If the hair is wet, all these conditions contribute to a much slower drying process, and can create a perfect environment for fungus and bacteria to thrive,' Schlabach said. 'If this happens often enough, it can grow into a real problem on the scalp causing yellow discoloration, itchiness, buildup and flakiness. All in all, it's gross. With enough buildup, it even stinks. I see it on new clients all the time.'
Fungi flourish in dark, moist and humid environments, and can live on the dead tissue of hair, nails and outer skin layers. As a result, your pillow is a breeding ground for fungus to thrive. A 2005 study by Wythenshawe Hospital and the University of Manchester found that there can be up to 16 types of fungal species found on your pillow.
You might also wake up with broken and tangled strands that can be hard to recover to their healthy state, especially for people with curly hair.
'The outside layer of the hair, the cuticle, is meant to expand when wet, and contract as it dries,' Schlabach said. 'If it stays stretched for too long, it can split and crack, compromising the health of that outer layer. It allows way too much penetration from water and products you might be using. This leads to dryness, which leads to brittleness, which leads to breakage, which visibly translates to stringy ends and frizz.'
In addition to hair breakage, we asked dermatologists about the types of fungal infections that can form in your hair, how your scalp is affected and what to do if you have to sleep with wet hair.
Types Of Fungal Infections
Malassezia
Malassezia species inhabit the skin of 90% of adults and usually don't cause any harm. The growth of these fungi may be attributed to humidity, sweating and oily skin, which can be a result of sleeping with wet hair.
Found in hair follicles, the fungus is also linked to a skin disease called dermatitis, a chronic form of eczema caused by genetic and environmental factors. An excess of Malassezia yeast can cause an immune system reaction that leads to fungal infections and skin changes.
Dermatitis is a broad category of conditions that share one common trait: they all cause inflammation of the skin, explained Dr. Peter Lio, an eczema expert and clinical assistant professor of dermatology and pediatrics at the Feinberg School of Medicine at Northwestern University.
'Typically this manifests as redness, swelling, scaling and dryness, but in more severe cases can actually cause things to open up and become oozing wounds,' said Lio, who is also a member of the National Eczema Association. 'On the scalp, the most common forms of dermatitis are seborrheic dermatitis and psoriasis, close cousins that typically manifest with flaking and scaling dandruff, dryness, and itch.'
Scalp Ringworm
Ringworm, or tinea capitis, is a fungal infection of the scalp hair. The fungi can make their way into your hair, affecting keratin and tissue, which causes your hair to become brittle and break. These fungi and their spores can remain on combs, brushes, unwashed towels, furniture and sheets for long periods.
Although most cases of scalp ringworm are caught from other people with the infection, one of the risk factors includes warm and humid environments where fungal spores may grow. Since fungi grow in wet environments, having wet skin or a wet scalp for a long period of time makes you more susceptible to developing the fungal infection.
'Despite the term 'ringworm,' there is no actual worm causing the rash,' explained Dr. Margarita Lolis, a board-certified dermatologist at Schweiger Dermatology Group in Hackensack, New Jersey. 'It got the name because of the circular patches it causes.'
The infection usually starts with red, round patches on the skin that may look like dandruff, causing itchiness, scale formation and alopecia. Similar to symptoms of dermatitis, ringworm can lead to patches of hair loss.
Although scalp ringworm is not a dangerous condition, it is contagious, Lolis said. 'If left untreated, it can lead to severe inflammation called kerion, which can drain pus and cause thick crusting on the scalp.'
Black Piedra
This rarer fungal infection affects the hair shafts by attaching to the hair and forming black nodules. Breakage of the hair can occur as a result of the nodules, and without treatment, the fungal infection may cause alopecia.
Black piedra is common in people with long hair with excessive hair oils, usually forming in hot and humid environments.
Unlike other forms of fungal infections, black piedra is asymptomatic and normal hair can be restored. However, it can be chronic, lasting for months or even years.
If You Sleep With Wet Hair, Try...
Drying Your Hair
It might be time to switch your shower schedule or try to let your hair air-dry before bed. However, if you don't have the time to wait for your hair to dry, blow-drying your hair might be better than sleeping with it wet.
'If a client needs to or prefers to shower at night, I'd highly recommend drying it before bed. For curly hair, use a diffuser to avoid heat damage,' Schlabach said. 'I tell my clients, 'If it's too hot for your skin, it's too hot for your hair.''
If you find yourself sleeping with wet hair regardless, it might be time to integrate products that can help prevent breakage and fungal infections.
Using A Silk Pillow
If you like to shower after a long day and don't have time for your hair to dry, a silk pillow can help to save your hair. Using a silk pillow can provide less friction on your hair when you're sleeping — even with wet hair, according to The Sleep Foundation, a non-profit that provides expert information for sleep issues.
Lea Brown, a hairstylist at Shine Aveda Salon + Spa in Sparks, Nevada, agreed. 'Wet hair is weak and can safely stretch up to 30% of its original length, stretching any further will cause breakage,' Brown told HuffPost. 'So, it's best to sleep with a silk or moisture-wicking fabric to prevent friction. Friction equals frizzy hair and breakage. Hair will have less shine, fullness and strength.'
Although a silk pillow can help to prevent breakage while you're sleeping, it doesn't completely prevent hair damage.
Using Anti-Fungal Products
Anti-fungal products such as shampoos and creams work to kill the yeast on your scalp and hair that causes infection and to prevent it from coming back. However, they do not clear the infection fully.
In addition to skin and hair products, oral anti-fungal medications might also be needed to treat infections that reach the root of the infected hair follicles. They can be prescribed by your doctor.
'Products that do treat the fungus, unfortunately, wind up drying out the hair, leaving it brittle and dull, leading to breakage and frizz,' Schlabach said. 'If they only knew to stop sleeping with wet hair in the first place — they wouldn't need to trade one issue for another.'
Switching Your Shower Routine
If you can make time to shower in the morning, it can help promote skin and hair health, Lolis said. 'Morning showers help combat oily hair and scalp. If you wash your hair at night, by the time you wake up it could still look oily. To ensure a fresh and clean style, it's best to wash in the morning.'
Additionally, since our body releases toxins and bacteria, such as sweat, while we're sleeping, showering in the morning removes sweat and buildup.
'There is no right or wrong time to shower, but the most important thing to remember is to ensure you are using lukewarm, not boiling hot water, and gentle soap to cleanse,' Lolis said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Next generation of doctors receive first class training in Bolton
Next generation of doctors receive first class training in Bolton

Yahoo

time3 days ago

  • Yahoo

Next generation of doctors receive first class training in Bolton

Student doctors are getting first class training in Bolton The University of Manchester has given Bolton NHS Foundation Trust a gold award for providing an 'excellent standard' to medical students who are on placement in Elderly Care and Microbiology. Students in the fifth year of their medical degree, who are asked to complete an evaluation of each placement they attend, provided an average score of 4.98 out of 5 for their experience at Royal Bolton Hospital. The evaluations highlight teams involved in the education of medical students who provide an excellent standard, which led to the University of Manchester to introduce Recognition of Excellence awards, based on the mean placement score. Dr Francis Andrews, Medical Director at Bolton NHS Foundation Trust, said: "We are incredibly proud of our status to delivering excellent standards when it comes to providing placements for the next generation of medical professionals. READ MORE: Bolton hospital bosses praised for approach to inclusivity How patients are helping shape treatment at Royal Bolton Hospital 'Do not ignore' letter which could save the lives of residents in this part of Bolton 'Medical placements are an important way to provide first-hand experience and for students to apply some of their learning to the real world.'A lot of time and dedication goes in to ensuring each our students receive tailored support, as well as skills and knowledge, to develop their careers and excel in their fields. Bolton welcomes a number of students in Elderly Care and Microbiology each year, where they are able to gain clinical experience in a hospital, including face-to-face patient contact, and complete work-based assessments, whilst being provided protected time to accommodate personal study and professional development. Professor David McKee, Undergraduate Hospital Dean at the University of Manchester, said: "Bolton's educational leadership has significantly contributed to achieving their score of 4.98 and a gold award. 'I recognise that delivering an excellent learning experience for students is a team effort. The Undergraduate Medical Education team are immensely proud of both our students' achievements and our engaged and supportive educators, who students tell us make such a difference to their learning. The gold award was presented to Bolton NHS Foundation Trust in a ceremony o

INBRAIN Neuroelectronics Reports Interim Analysis of First-in-Human Study of Graphene Brain-Computer Interface
INBRAIN Neuroelectronics Reports Interim Analysis of First-in-Human Study of Graphene Brain-Computer Interface

Yahoo

time29-07-2025

  • Yahoo

INBRAIN Neuroelectronics Reports Interim Analysis of First-in-Human Study of Graphene Brain-Computer Interface

Graphene-based BCI demonstrates high-resolution brain decoding and mapping in patients undergoing tumor resection at the Manchester Centre for Clinical Neurosciences Initial four patient cohort has shown no safety concerns to date that would prevent the completion of this first-in-human study. BARCELONA, Spain, July 29, 2025--(BUSINESS WIRE)--INBRAIN Neuroelectronics today announced the interim analysis of findings from the world's first-in-human clinical study of its graphene-based brain-computer interface (BCI) technology. The study, sponsored by the University of Manchester and conducted at the Manchester Centre for Clinical Neurosciences (Northern Care Alliance NHS Foundation Trust), is evaluating the safety and functional performance of graphene-based electrodes when used during surgery for resection of brain tumors. The primary objective of the study (NCT06368310) is to assess the safety of INBRAIN's brain-computer interface (BCI) during brain tumor surgery. Secondary objectives include evaluating the quality of neural signals captured by the device, its ability to deliver targeted brain stimulation, the consistency of its performance throughout the procedure, and its overall suitability for use in the neurosurgical operating room. A total of 8 to 10 patients are expected to be enrolled to validate the safety and functional performance of the graphene-based BCI. The study design included an interim analysis after the first four patients had been recruited to ensure patient safety and data quality. Interim analysis of the results from the first cohort of four patients enrolled in the study demonstrated no device-related adverse events, a key component of the primary endpoint of the study. During awake language mapping, the device captured distinct high gamma activity linked to different phonemes, the smallest units of sound in speech, showcasing exceptional spatial and temporal resolution, even with micrometer-scale contacts. The ultra-thin, sub-micrometer graphene electrodes also proved compatible with commercially available, CE-marked electrophysiology systems, reliably recording real-time brain signals throughout the surgical procedures. "The ability to detect high-frequency neural activity with micrometer-scale precision opens new possibilities for understanding brain-tumor interactions and broader brain function in neuro-related disorders," said Mr. David Coope, Chief Investigator and Consultant Neurosurgeon at the Manchester Centre for Clinical Neurosciences, the Geoffrey Jefferson Brain Research Centre and the University of Manchester. "This technology could be transformative, not only for improving surgical outcomes but for unlocking new treatment pathways." Throughout the procedures, INBRAIN's BCI enabled high-resolution brain signal monitoring, addressing one of the most pressing challenges in neurosurgery: achieving precise tumor removal while preserving essential functions such as speech, movement, and cognition. The device was used in parallel with standard clinical monitoring tools, maintaining consistent performance across the surgical window. "This milestone demonstrates that graphene-based brain-computer interfaces can be deployed in the operating room and deliver a level of neural fidelity not achievable with traditional materials," said Carolina Aguilar, CEO and Co-Founder, INBRAIN Neuroelectronics. "We're moving toward a future where neurosurgeons and neurologists can rely on real-time, high-definition brain data to guide personalized interventions." INBRAIN's platform is powered by ultra-flexible, thin-film graphene semiconductors that conform more precisely to the brain surface than conventional strip electrodes. The BCI features high-density, multiscale, bidirectional contacts for superior decoding and modulation, and reduced graphene oxide (rGO) nanoporous matrices that enhance sensitivity and signal resolution. In preclinical studies, the GCI significantly outperformed platinum-based electrodes in detecting high gamma frequencies (80–130 Hz) critical for speech decoding, with statistical significance (p < 0.01). Clinical Advantages Graphene technology offers several benefits for neurosurgical procedures. It enhances surgical precision by enabling smaller and more densely packed electrodes, allowing surgeons to define and preserve critical functional areas during tumor resection. Its flexibility enables accurate decoding and mapping in anatomically complex or hard-to-access brain regions, including the walls of the tumor resection cavity. Additionally, the device's ability to decode high-frequency activity offers huge scientific opportunities including the potential to reveal in situ interactions between glioma cells and neurons, offering potential insights into new therapeutic targets for halting tumor progression. "We're not delivering incremental innovation, we're enabling entirely new capabilities," said Kostas Kostarelos, Co-Founder of INBRAIN and Chief Scientific Investigator of the study and Professor of Nanomedicine at the University of Manchester, the Catalan Institute of Nanoscience and Nanotechnology (ICN2) in Barcelona, and Programme Lead for the Next Generation Therapeutics Theme of the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC). "This convergence of advanced materials science, neuroscience, and AI is shaping the future of real-time, precision neurology." As the first safety study of a graphene-based neural interface in humans, this study marks a foundational step toward the development of BCI therapeutic systems for chronic neurological diseases, pioneering a new era of real-time, precision neurology. About INBRAIN Neuroelectronics INBRAIN Neuroelectronics is pioneering real-time precision neurology with the world's first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit and follow us on LinkedIn. About Northern Care Alliance (NCA) Northern Care Alliance NHS Foundation Trust provides hospital and community healthcare services in Salford, Oldham, Bury and Rochdale. Our dedicated team of around 20,000 staff delivers high standards of care and experience excellence to over one million people across Greater Manchester and beyond, working together to save lives and improve lives. More information about the NCA can be found at About the National Institute for Health and Care Research (NIHR) The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by: Funding high quality, timely research that benefits the NHS, public health and social care; Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services; Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research; Attracting, training and supporting the best researchers to tackle complex health and social care challenges; Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system; Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries. NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK international development funding from the UK government. About the NIHR Manchester Biomedical Research Centre (BRC) The NIHR Manchester Biomedical Research Centre (BRC) transforms scientific breakthroughs into diagnostic tests and life-saving treatments for patients. NIHR Biomedical Research Centres (BRCs) are collaborations between NHS organisations and universities. They bring together academics and clinicians to translate scientific discoveries into potential new treatments, diagnostics and technologies. Manchester BRC is hosted by Manchester University NHS Foundation Trust and The University of Manchester – in partnership with five NHS trusts; Blackpool Teaching Hospitals NHS Foundation Trust, The Christie NHS Foundation Trust, Greater Manchester Mental Health NHS Foundation Trust, Lancashire Teaching Hospitals NHS Foundation Trust, and the Northern Care Alliance NHS Foundation Trust. About The University of Manchester The University of Manchester is recognised globally for its pioneering research, outstanding teaching and learning, and commitment to social responsibility. The Russell Group institution is ranked the 6th best university in the UK and 38th in the world (Academic Ranking of World Universities). A truly international university, its community includes more than 44,000 students, 12,000 staff, and 500,000 alumni from 190 countries. Together, they are tackling the world's biggest challenges – the University's social and environmental impact is ranked in the top ten globally (Times Higher Education Impact Rankings). The University is a powerhouse of research and discovery; 25 Nobel laureates are among its former staff and students; and it was ranked fifth for research power – the quality and scale of research and impact – in the UK government's Research Excellence Framework (REF) 2021. The institution is the most popular in the UK for undergraduate applications (UCAS 2021 cycle), and it is the it is the most targeted university by the UK's leading employers (The Graduate Market, 2023). View source version on Contacts Media Kimberly HaKKH Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

INBRAIN Neuroelectronics Reports Interim Analysis of First-in-Human Study of Graphene Brain-Computer Interface
INBRAIN Neuroelectronics Reports Interim Analysis of First-in-Human Study of Graphene Brain-Computer Interface

Business Wire

time29-07-2025

  • Business Wire

INBRAIN Neuroelectronics Reports Interim Analysis of First-in-Human Study of Graphene Brain-Computer Interface

BARCELONA, Spain--(BUSINESS WIRE)-- INBRAIN Neuroelectronics today announced the interim analysis of findings from the world's first-in-human clinical study of its graphene-based brain-computer interface (BCI) technology. The study, sponsored by the University of Manchester and conducted at the Manchester Centre for Clinical Neurosciences (Northern Care Alliance NHS Foundation Trust), is evaluating the safety and functional performance of graphene-based electrodes when used during surgery for resection of brain tumors. The primary objective of the study (NCT06368310) is to assess the safety of INBRAIN's brain-computer interface (BCI) during brain tumor surgery. Secondary objectives include evaluating the quality of neural signals captured by the device, its ability to deliver targeted brain stimulation, the consistency of its performance throughout the procedure, and its overall suitability for use in the neurosurgical operating room. A total of 8 to 10 patients are expected to be enrolled to validate the safety and functional performance of the graphene-based BCI. The study design included an interim analysis after the first four patients had been recruited to ensure patient safety and data quality. Interim analysis of the results from the first cohort of four patients enrolled in the study demonstrated no device-related adverse events, a key component of the primary endpoint of the study. During awake language mapping, the device captured distinct high gamma activity linked to different phonemes, the smallest units of sound in speech, showcasing exceptional spatial and temporal resolution, even with micrometer-scale contacts. The ultra-thin, sub-micrometer graphene electrodes also proved compatible with commercially available, CE-marked electrophysiology systems, reliably recording real-time brain signals throughout the surgical procedures. 'The ability to detect high-frequency neural activity with micrometer-scale precision opens new possibilities for understanding brain-tumor interactions and broader brain function in neuro-related disorders,' said Mr. David Coope, Chief Investigator and Consultant Neurosurgeon at the Manchester Centre for Clinical Neurosciences, the Geoffrey Jefferson Brain Research Centre and the University of Manchester. 'This technology could be transformative, not only for improving surgical outcomes but for unlocking new treatment pathways.' Throughout the procedures, INBRAIN's BCI enabled high-resolution brain signal monitoring, addressing one of the most pressing challenges in neurosurgery: achieving precise tumor removal while preserving essential functions such as speech, movement, and cognition. The device was used in parallel with standard clinical monitoring tools, maintaining consistent performance across the surgical window. 'This milestone demonstrates that graphene-based brain-computer interfaces can be deployed in the operating room and deliver a level of neural fidelity not achievable with traditional materials,' said Carolina Aguilar, CEO and Co-Founder, INBRAIN Neuroelectronics. 'We're moving toward a future where neurosurgeons and neurologists can rely on real-time, high-definition brain data to guide personalized interventions.' INBRAIN's platform is powered by ultra-flexible, thin-film graphene semiconductors that conform more precisely to the brain surface than conventional strip electrodes. The BCI features high-density, multiscale, bidirectional contacts for superior decoding and modulation, and reduced graphene oxide (rGO) nanoporous matrices that enhance sensitivity and signal resolution. In preclinical studies, the GCI significantly outperformed platinum-based electrodes in detecting high gamma frequencies (80–130 Hz) critical for speech decoding, with statistical significance (p < 0.01). Clinical Advantages Graphene technology offers several benefits for neurosurgical procedures. It enhances surgical precision by enabling smaller and more densely packed electrodes, allowing surgeons to define and preserve critical functional areas during tumor resection. Its flexibility enables accurate decoding and mapping in anatomically complex or hard-to-access brain regions, including the walls of the tumor resection cavity. Additionally, the device's ability to decode high-frequency activity offers huge scientific opportunities including the potential to reveal in situ interactions between glioma cells and neurons, offering potential insights into new therapeutic targets for halting tumor progression. 'We're not delivering incremental innovation, we're enabling entirely new capabilities,' said Kostas Kostarelos, Co-Founder of INBRAIN and Chief Scientific Investigator of the study and Professor of Nanomedicine at the University of Manchester, the Catalan Institute of Nanoscience and Nanotechnology (ICN2) in Barcelona, and Programme Lead for the Next Generation Therapeutics Theme of the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC). 'This convergence of advanced materials science, neuroscience, and AI is shaping the future of real-time, precision neurology.' As the first safety study of a graphene-based neural interface in humans, this study marks a foundational step toward the development of BCI therapeutic systems for chronic neurological diseases, pioneering a new era of real-time, precision neurology. About INBRAIN Neuroelectronics INBRAIN Neuroelectronics is pioneering real-time precision neurology with the world's first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit and follow us on LinkedIn. About Northern Care Alliance (NCA) Northern Care Alliance NHS Foundation Trust provides hospital and community healthcare services in Salford, Oldham, Bury and Rochdale. Our dedicated team of around 20,000 staff delivers high standards of care and experience excellence to over one million people across Greater Manchester and beyond, working together to save lives and improve lives. More information about the NCA can be found at About the National Institute for Health and Care Research (NIHR) The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by: Funding high quality, timely research that benefits the NHS, public health and social care; Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services; Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research; Attracting, training and supporting the best researchers to tackle complex health and social care challenges; Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system; Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries. NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK international development funding from the UK government. About the NIHR Manchester Biomedical Research Centre (BRC) The NIHR Manchester Biomedical Research Centre (BRC) transforms scientific breakthroughs into diagnostic tests and life-saving treatments for patients. NIHR Biomedical Research Centres (BRCs) are collaborations between NHS organisations and universities. They bring together academics and clinicians to translate scientific discoveries into potential new treatments, diagnostics and technologies. Manchester BRC is hosted by Manchester University NHS Foundation Trust and The University of Manchester – in partnership with five NHS trusts; Blackpool Teaching Hospitals NHS Foundation Trust, The Christie NHS Foundation Trust, Greater Manchester Mental Health NHS Foundation Trust, Lancashire Teaching Hospitals NHS Foundation Trust, and the Northern Care Alliance NHS Foundation Trust. About The University of Manchester The University of Manchester is recognised globally for its pioneering research, outstanding teaching and learning, and commitment to social responsibility. The Russell Group institution is ranked the 6 th best university in the UK and 38 th in the world (Academic Ranking of World Universities). A truly international university, its community includes more than 44,000 students, 12,000 staff, and 500,000 alumni from 190 countries. Together, they are tackling the world's biggest challenges – the University's social and environmental impact is ranked in the top ten globally (Times Higher Education Impact Rankings). The University is a powerhouse of research and discovery; 25 Nobel laureates are among its former staff and students; and it was ranked fifth for research power – the quality and scale of research and impact – in the UK government's Research Excellence Framework (REF) 2021. The institution is the most popular in the UK for undergraduate applications (UCAS 2021 cycle), and it is the it is the most targeted university by the UK's leading employers (The Graduate Market, 2023).

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store